A triple action chemosensor (R1) bearing a rhodamine and thiophene moiety was synthesized by a simple condensation reaction. The sensing behaviour and selectivity of the synthesized chemosensor toward metal ions were studied by UV-Vis and fluorescence spectroscopy. The chemosensor recognized Cu and Cr ions with significant changes in UV-Vis absorbance and fluorescence intensity. The results showed that Cr induced greater fluorescence enhancement whereas Cu ions bound strongly with the receptor by showing a strong absorption band at 554 nm but with weak fluorescence. A visible colour change was observed by the addition of Cu and that colour change is due to the opening of the spirolactam ring triggered by the addition of Cu ions. Job's plot analysis indicated a 1 : 2 and 1 : 1 binding stoichiometry between the chemosensor and Cr/Cu. Subsequently, the R1 - Cu complex chemosensor was employed to detect CN in the presence of different anions, such as F, Cl, Br, I, AcO, HPO, HSO, NO and OH. In addition, the live cell imaging of HeLa cells using R1 and Cr was demonstrated successfully.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c7pp00163k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Elexacaftor, Tezacaftor and Ivacaftor: immediate efficacy evaluation using home spirometry].
Rev Mal Respir
January 2025
Unité de pneumologie adulte, centre de mucoviscidose liégeois, CHC MontLégia, Liège, Belgique.
Introduction: Following two weeks of application of the triple combination therapy of Elexacaftor (E), Tezacaftor (T), and Ivacaftor (I) known as ETI, substantial pulmonary improvement in patients with cystic fibrosis is well-documented. However, few detailed data are available on the action of this treatment over the course of these first 14 days.
Methods: In this prospective study (NCT05599230), 20 patients aged≥12 years, all of them eligible for ETI, were recruited at the initiation of treatment.
Secernin-2 Stabilizes Histone Methyltransferase KMT2C to Suppress Progression and Confer Therapeutic Sensitivity to PARP Inhibition in Triple-Negative Breast Cancer.
Adv Sci (Weinh)
January 2025
Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Triple-negative breast cancer (TNBC) is a difficulty and bottleneck in the clinical treatment of breast cancer due to a lack of effective therapeutic targets. Herein, we first report that secernin 2 (SCRN2), an uncharacterized gene in human cancer, acts as a novel tumor suppressor in TNBC to inhibit cancer progression and enhance therapeutic sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition both in vitro and in vivo. SCRN2 is downregulated in TNBC through chaperone-mediated autophagic degradation, and its downregulation is associated with poor patient prognosis.
View Article and Find Full Text PDFA Three-agent Regimen for Triple Negative Breast Cancer Treatment.
Recent Pat Anticancer Drug Discov
January 2025
Department of Medical Oncology, Affiliated Hospital of Inner Mongolia Medical University, NO1 Tongdao Northern Road, Hohhot, 010050, China.
Background: Triple-negative breast cancer (TNBC) has a poor prognosis with current treatment options. Novel therapeutic strategies are urgently needed to enhance treatment outcomes for TNBC.
Objective: This study evaluated the efficacy of a three-agent regimen compared to existing treatment regimens in a TNBC mouse model, and elucidated its potential mechanisms of action.
Cisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy.
Biomed Pharmacother
January 2025
Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno CZ-61200, Czech Republic; Department of Biophysics, Faculty of Science, Palacky University, Slechtitelu 27, Olomouc 783 71, Czech Republic. Electronic address:
Platinum(IV) compounds possess distinct properties that set them apart from platinum(II) compounds. Often designed as prodrugs, they are reduced within cancer cells to their active platinum(II) form, enabling their cytotoxic effects. Their versatility also lies in their ability to be functionalized and conjugated with bioactive molecules to enhance cancer cell targeting.
View Article and Find Full Text PDFEvaluation of the adherence of municipalities and states to the Ministry of Health's microplanning for high-quality vaccination activities and the increase in vaccination coverage in Brazil.
BMC Public Health
January 2025
Diretor do Programa Nacional de Imunizações, Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Departamento de Doenças Imunopreveníveis, Doutor em Saúde Coletiva pela Faculdade de Medicina da Universidade de São Paulo - FMUSP, Brasília, Brazil.
Background: Immunization is a significant public health achievement for the whole world, although the population's adherence to vaccination efforts remains a concern. To address this, Brazil's Ministry of Health introduced the concept of operational microplanning (OM) for high-quality vaccination activities (HQVA) in 2023 to ensure excellence in routine service and campaigns. OM is defined by structured interventions using assertive techniques to enhance the likelihood of covering a broader population previously unprotected from vaccine-preventable diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!